Enterprise AI startup Kumo is making the case that the next phase of enterprise AI will be shaped by structured and ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral ...

Abstract: Deep neural network (DNN)-based inversion of ground penetrating radar (GPR) data is gaining significant attention, primarily using simulated data for training due to the lack of ground truth ...

The rapid development of protein structure prediction tools has created a need for systematic performance comparisons to guide method selection for different applications, particularly given the trade ...

Schema Compare shows the differences between two database structures. It highlights changes in a clean diff view and generates scripts to align one side with the other. See Schema Compare guide.

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

The reported cryo-EM imaging of a pentameric ligand-gated ion channel in liposomes as opposed to nanodiscs has both broad implications and contributes valuable methodological advances to the ...